CVE:SVA Sernova Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sernova Corp. Please log in to your account or sign up in order to add this asset to your watchlist. C$1.57 +0.09 (+6.08%) (As of 06/1/2022) Add Compare Share Today's RangeC$1.46▼C$1.5750-Day RangeC$1.38▼C$1.5752-Week RangeC$1.16▼C$2.22Volume121,355 shsAverage Volume288,358 shsMarket CapitalizationC$432.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesHeadlinesOptions ChainSocial Media Sernova MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring SharesC$64.50 K Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.39 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Sernova. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for SVA. Previous Next 0.0 Dividend Strength Dividend YieldSernova does not currently pay a dividend.Dividend GrowthSernova does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SVA. Previous Next 1.1 News and Social Media Coverage News SentimentSernova has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.MarketBeat FollowsOnly 10 people have added Sernova to their MarketBeat watchlist in the last 30 days. This is a decrease of -9% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sernova insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$64,500.00 in company stock and sold C$0.00 in company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Sernova is -37.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sernova is -37.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSernova has a P/B Ratio of 15.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sernova and its competitors with MarketBeat's FREE daily newsletter. Email Address About Sernova (CVE:SVA) StockSernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells, which then release proteins and/or hormones for the long-term treatment of various serious chronic diseases, such as diabetes, hemophilia, and thyroid disease. Sernova Corp. has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected therapeutic cells; and a research agreement with the University of Miami to advance the development of Cell Pouch cell therapy platform. The company was incorporated in 1998 and is headquartered in London, Canada.Read More SVA Stock News HeadlinesJune 22, 2022 | americanbankingnews.comSernova Corp. (CVE:SVA) Director Frank Holler Purchases 50,000 Shares of StockJune 15, 2022 | globenewswire.comSernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in June - GlobeNewswireJune 15, 2022 | finance.yahoo.comSernova to Participate in the Truist Securities Cell Therapy Symposium, Symposia-cel in JuneJune 10, 2022 | ca.finance.yahoo.comSernova Corp. (SVA.TO)June 6, 2022 | globenewswire.comSernova Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System™ at American Diabetes Association 82nd Scientific Sessions 2022 - GlobeNewswireJune 2, 2022 | finance.yahoo.comOligomerix Announces Series B Extension Raise of $2.7 Million to Support Phase 1 Clinical Development - Yahoo FinanceJune 2, 2022 | finance.yahoo.comAltos Labs Announces Sponsored Research Agreement with Kyoto University's CiRA to Foster Cellular Rejuvenation Programming Research - Yahoo FinanceJune 2, 2022 | finance.yahoo.comTScan Therapeutics to Participate in the 2022 Jefferies Healthcare Conference - Yahoo FinanceMay 17, 2022 | globenewswire.comSernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a 'Functional Cure' for Diabetes - GlobeNewswireMay 17, 2022 | finance.yahoo.comSernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes - Yahoo FinanceMay 17, 2022 | finance.yahoo.comEvotec and Sernova Announce Exclusive Strategic Partnership for iPSC-based Beta Cell Replacement Therapy to Advance a 'Functional Cure' for Diabetes - Yahoo FinanceMarch 24, 2022 | businesswire.com2022 Global Conformal Coatings Technology Growth Opportunities - ResearchAndMarkets.com - Business WireJanuary 10, 2022 | ca.finance.yahoo.comIIROC Trading Halt - SVADecember 27, 2021 | finance.yahoo.comWe Think Sernova (CVE:SVA) Can Easily Afford To Drive Business GrowthNovember 16, 2021 | uk.finance.yahoo.comSernova to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services ForumJuly 28, 2021 | uk.finance.yahoo.comSernova Corp. (SVA.V)October 16, 2020 | ca.finance.yahoo.comSernova Corp. Registered Shares (PSH.SG)October 13, 2020 | au.finance.yahoo.comSERNOVA CORP. (PSH.MU)August 17, 2020 | ca.finance.yahoo.comSernova Corp. (PSH.F)August 1, 2020 | au.finance.yahoo.comSERNOVA CORP. (PSH.BE)May 29, 2020 | www.businesswire.comAgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia AJuly 3, 2019 | www.baystreet.caInvestors Cheer Sernova DataMay 21, 2019 | www.marketwatch.comSernova Corp Announces Appointment of Deborah Brown to its Board of DirectorsSee More Headlines Industry, Sector and Symbol Stock ExchangeCVE Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolCVE:SVA CUSIPN/A CIKN/A Webwww.sernova.com Phone+1-519-8585184FaxN/AEmployees1,959Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1.34 Current Ratio13.76 Quick Ratio13.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.10 per share Price / Cash Flow15.10 Book ValueC$0.10 per share Price / Book15.10Miscellaneous Outstanding Shares275,525,000Free FloatN/AMarket CapC$432.57 million OptionableOptionable BetaN/A Sernova Frequently Asked Questions Should I buy or sell Sernova stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sernova in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sernova stock. View analyst ratings for Sernova or view top-rated stocks. How has Sernova's stock performed in 2022? Sernova's stock was trading at C$1.82 at the start of the year. Since then, SVA shares have decreased by 13.7% and is now trading at C$1.57. View the best growth stocks for 2022 here. Who are some of Sernova's key competitors? Some companies that are related to Sernova include MaxCyte (MXCT), Profound Medical (PRN), Profound Medical (PRN), Renalytix (RENX), Akumin (AKU), SQI Diagnostics (SQD), Oncimmune (ONC), Yourgene Health (YGEN), Verici Dx (VRCI), VentriPoint Diagnostics (VPT), Cambridge Cognition (COG), GeneNews (GEN), LexaGene (LXG), GENinCode (GENI) and genedrive (GDR). View all of SVA's competitors. What other stocks do shareholders of Sernova own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sernova investors own include Gilead Sciences (GILD), New Residential Investment (NRZ), SMART Global (SGH), Big Lots (BIG), Bernstein U.S. Research Fund (BERN), Bank of America (BAC), Alibaba Group (BABA), AstraZeneca (AZN), Liberty All-Star Growth Fund (ASG) and Ares Capital (ARCC). What is Sernova's stock symbol? Sernova trades on the Canadian Venture Exchange (CVE) under the ticker symbol "SVA." How do I buy shares of Sernova? Shares of SVA and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What is Sernova's stock price today? One share of SVA stock can currently be purchased for approximately C$1.57. How much money does Sernova make? Sernova (CVE:SVA) has a market capitalization of C$432.57 million. How many employees does Sernova have? Sernova employs 1,959 workers across the globe. How can I contact Sernova? Sernova's mailing address is 700 Collip Cir Suite 114, LONDON, ON N6G 4X8, Canada. The official website for Sernova is www.sernova.com. The company can be reached via phone at +1-519-8585184. This page (CVE:SVA) was last updated on 7/3/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
